LENVIMA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States

Active ingredients

The drug LENVIMA contains one active pharmaceutical ingredient (API):

1 Lenvatinib UNII 3J78384F61 - LENVATINIB MESYLATE

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET. Read about Lenvatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LENVIMA Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX08		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10952K, 10965D, 11638M
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 533219110002217, 533219110002317
Country: CA	Health Products and Food Branch	Identifier(s): 02450291, 02450305, 02450313, 02450321, 02468220, 02468239, 02484056, 02484129
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 5275-MEE-0720, 5280-MEE-0720
Country: EE	Ravimiamet	Identifier(s): 1687181, 1687192, 1818817, 1818828, 1818851, 1818862, 1849697, 1849709
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1151002001, 1151002002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 387479, 478672
Country: FR	Base de données publique des médicaments	Identifier(s): 62093424, 64456664
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 298651, 298654
Country: HK	Department of Health Drug Office	Identifier(s): 64507, 64508
Country: IE	Health Products Regulatory Authority	Identifier(s): 88386, 88391
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7824, 7825
Country: IT	Agenzia del Farmaco	Identifier(s): 044200018, 044200020, 044200032, 044200044, 044200057, 044200069
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291039M1020, 4291039M2027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1076775, 1076776, 1090398, 1090399, 1090400, 1090401
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 133256, 133299
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 20962, 20963
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100347485, 100347491
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66655001, W66655002, W66655003, W66656001, W66656002, W66656003
Country: SG	Health Sciences Authority	Identifier(s): 14982P, 14983P
Country: US	FDA, National Drug Code	Identifier(s): 62856-704, 62856-708, 62856-710, 62856-712, 62856-720